Should I buy or sell Aditxt stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aditxt in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADTX shares. View ADTX analyst ratings or view top-rated stocks .

What is Aditxt's stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Aditxt's stock. Their ADTX share price targets range from $61.00 to $61.00. On average, they expect the company's stock price to reach $61.00 in the next twelve months. This suggests a possible upside of 2,484.7% from the stock's current price. View analysts price targets for ADTX or view top-rated stocks among Wall Street analysts .

How have ADTX shares performed in 2024?

Aditxt's stock was trading at $6.63 at the beginning of 2024. Since then, ADTX stock has decreased by 64.4% and is now trading at $2.36. View the best growth stocks for 2024 here .

Are investors shorting Aditxt?

Aditxt saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 19,500 shares, a decline of 44.4% from the March 15th total of 35,100 shares. Based on an average daily volume of 391,600 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.0% of the shares of the company are sold short. View Aditxt's Short Interest .

When is Aditxt's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ADTX earnings forecast .

How were Aditxt's earnings last quarter?

Aditxt, Inc. (NASDAQ:ADTX) issued its quarterly earnings data on Wednesday, August, 11th. The company reported ($840.00) EPS for the quarter, missing analysts' consensus estimates of ($100.00) by $740.00.

When did Aditxt's stock split?

Aditxt shares reverse split before market open on Friday, August 18th 2023. The 1-40 reverse split was announced on Friday, August 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Aditxt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aditxt investors own include Tesla (TSLA) , Dynavax Technologies (DVAX) , Boeing (BA) , CrowdStrike (CRWD) , Genius Brands International (GNUS) , Nikola (NKLA) , Block (SQ) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) and Arbutus Biopharma (ABUS) .

How do I buy shares of Aditxt?

Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ADTX

Aditxt (ADTX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ADTX Stock Alerts

$2.36

-0.05 (-2.07%)

(As of 09:36 AM ET)

Compare

Today's Range: $2.36
▼
$2.48
50-Day Range: $2.35
▼
$4.00
52-Week Range: $2.28
▼
$76.40

Volume: 4,921 shs
Average Volume: 357,579 shs
Market Capitalization: $566,400.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $61.00

Get Aditxt alerts:

Aditxt MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,484.7% Upside
$61.00 Price Target
Short Interest: Healthy
0.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.38 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Aditxt has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aditxt has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.99% of the float of Aditxt has been sold short.
Short Interest Ratio / Days to Cover
Aditxt has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aditxt has recently decreased by 44.44%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aditxt does not currently pay a dividend.
Dividend Growth
Aditxt does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADTX.

2.4

News and Social Media Coverage

News Sentiment
Aditxt has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aditxt this week, compared to 2 articles on an average week.
Search Interest
Only 10 people have searched for ADTX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aditxt insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.23% of the stock of Aditxt is held by insiders.
Percentage Held by Institutions
Only 15.54% of the stock of Aditxt is held by institutions.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
Aditxt has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Aditxt Stock (NASDAQ:ADTX)

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

ADTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ADTX Stock News Headlines

April 11, 2024 | americanbankingnews.com

Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 44.4% in March

April 2, 2024 | marketwatch.com

Aditxt to Buy Biopharmaceutical Company Appili Therapeutics for Undisclosed Amount

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.

April 2, 2024 | markets.businessinsider.com

Appili Therapeutics To Be Acquired By Aditxt

April 2, 2024 | businesswire.com

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

March 27, 2024 | finanznachrichten.de

Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

March 27, 2024 | prnewswire.com

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

March 20, 2024 | prnewswire.com

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal

April 19, 2024 | Altimetry (Ad)

I’m officially sounding the alarm.

March 7, 2024 | prnewswire.com

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

February 10, 2024 | markets.businessinsider.com

Aditxt CEO Provides Short-Term Loan to Bolster Stability

February 10, 2024 | msn.com

Aditxt, Inc. Enters New Financial Obligation Impacting Investors

February 3, 2024 | msn.com

Aditxt Announces Merger Agreement with Evofem Biosciences

January 30, 2024 | msn.com

Aditxt buys Brain Scientific's portfolio of EEG brain monitoring technologies and devices

January 30, 2024 | finance.yahoo.com

Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

January 18, 2024 | msn.com

Aditxt files to sell 3.79M shares for holders

January 14, 2024 | benzinga.com

Aditxt Stock (NASDAQ:ADTX), Short Interest Report

January 13, 2024 | benzinga.com

Aditxt Stock (NASDAQ:ADTX) Dividends: History, Yield and Dates

January 8, 2024 | finance.yahoo.com

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

January 5, 2024 | finance.yahoo.com

Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

January 3, 2024 | bizjournals.com

Richmond's Aditxt reaches deal to acquire maker of Phexxi

January 3, 2024 | marketwatch.com

Aditxt Shares Drop 24% After Pricing of Private Placement

January 2, 2024 | finance.yahoo.com

Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement

December 29, 2023 | finance.yahoo.com

Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules

December 29, 2023 | benzinga.com

What's Going On With Aditxt Stock?

December 12, 2023 | msn.com

Why Is Life Sciences-Focused Aditxt Stock Trading Higher Today?

December 12, 2023 | markets.businessinsider.com

Crude Oil Down 4%; Aditxt Shares Spike Higher

See More Headlines

Receive ADTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aditxt and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ADTX
CUSIP: N/A
CIK: 1726711
Web: www.aditxt.com
Phone: 650-870-1200
Fax: N/A
Employees: 61
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $61.00
High Stock Price Target: $61.00
Low Stock Price Target: $61.00
Potential Upside/Downside: +2,431.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,650,000.00
Net Margins: -3,946.13%
Pretax Margin: -3,946.13%
Return on Equity: N/A
Return on Assets: -349.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.30
Quick Ratio: 0.23

Sales & Book Value

Annual Sales: $640,000.00
Price / Sales: 0.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $50.04 per share
Price / Book: 0.05

Miscellaneous

Outstanding Shares: 240,000
Free Float: 236,000
Market Cap: $578,400.00
Optionable: No Data
Beta: 1.29

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Amro A. Albanna (Age 54)
Co-Founder, Chairman & CEO
Comp: $472.12k
Dr. Shahrokh Shabahang D.D.S. (Age 61)
M.S., Ph.D., Co-Founder, Chief Innovation Officer, Secretary & Director
Comp: $323.5k
Mr. Thomas J. Farley CPA (Age 51)
Chief Financial Officer
Comp: $357.89k
Ms. Corinne D. Pankovcin CPA (Age 58)
M.B.A., Chief Commercialization Officer
Comp: $366.77k
Ms. Rowena Albanna (Age 58)
Chief Operating Officer
Ms. Jennifer Lee
Director of Human Resources
Dr. Dolly B. Tyan Ph.D.
Senior Vice President of Clinical Development Transplantation
Mr. Ge Chen M.D.
M.S., Senior Vice President of Preclinical Research & Discovery

Key Competitors

View All Competitors

Insiders

Paribas Securities Corp Bnp
Sold 20,800 shares
Total: $691,184.00 ($33.23/share)

View All Insider Transactions

ADTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Aditxt stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aditxt in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADTX shares.
View ADTX analyst ratings or view top-rated stocks.
What is Aditxt's stock price target for 2024?: 1 equities research analysts have issued twelve-month target prices for Aditxt's stock. Their ADTX share price targets range from $61.00 to $61.00. On average, they expect the company's stock price to reach $61.00 in the next twelve months. This suggests a possible upside of 2,484.7% from the stock's current price.
View analysts price targets for ADTX or view top-rated stocks among Wall Street analysts.
How have ADTX shares performed in 2024?: Aditxt's stock was trading at $6.63 at the beginning of 2024. Since then, ADTX stock has decreased by 64.4% and is now trading at $2.36.
View the best growth stocks for 2024 here.
Are investors shorting Aditxt?: Aditxt saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 19,500 shares, a decline of 44.4% from the March 15th total of 35,100 shares. Based on an average daily volume of 391,600 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.0% of the shares of the company are sold short.
View Aditxt's Short Interest.
When is Aditxt's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ADTX earnings forecast.

How were Aditxt's earnings last quarter?: Aditxt, Inc. (NASDAQ:ADTX) issued its quarterly earnings data on Wednesday, August, 11th. The company reported ($840.00) EPS for the quarter, missing analysts' consensus estimates of ($100.00) by $740.00.
When did Aditxt's stock split?: Aditxt shares reverse split before market open on Friday, August 18th 2023. The 1-40 reverse split was announced on Friday, August 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of Aditxt own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aditxt investors own include Tesla (TSLA), Dynavax Technologies (DVAX), Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA), Block (SQ), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Arbutus Biopharma (ABUS).
How do I buy shares of Aditxt?: Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial